Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Alnylam Pharmaceuticals Inc | 571 |
| 2 | Moderna Inc | 217 |
| 3 | Johnson and Johnson | 117 |
| 4 | AstraZeneca PLC | 112 |
| 5 | Arbutus Biopharma Corp | 77 |
| 6 | Novartis AG | 71 |
| 7 | Sanofi SA | 71 |
| 8 | Harvard University | 63 |
| 9 | Siemens AG | 63 |
| 10 | Bayer AG | 59 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 3,442 |
| 2 | A61P | Therapeutic activity (drug indications) | 3,153 |
| 3 | C12N | Microorganisms, enzymes | 1,829 |
| 4 | C07K | Peptides | 1,582 |
| 5 | C07D | Heterocyclic compounds | 626 |
| 6 | G01N | Investigating / analysing materials | 609 |
| 7 | C07H | Sugars and derivatives | 419 |
| 8 | C12Y | Enzyme nomenclature (EC numbers) | 396 |
| 9 | Y02A | Climate change adaptation | 359 |
| 10 | A61Q | Cosmetics, personal care | 301 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Intermedin analogue prepared by bonding ring core sequence with biotin or cell-penetrating peptides | 2012 | 55 | |
| THERAPEUTIC USES OF INTERMEDIN 47 AND 53 PEPTIDES | 2009 | Relief Therapeutics Holding SA | 6 |
| Therapeutic use of intermedin 47 peptide and intermedin 53 peptide | 2010 | 0 | |
| THERAPEUTIC USES OF INTERMEDIN 47 AND 53 PEPTIDES | 2009 | Relief Therapeutics Holding SA | 0 |
| USE OF INTERMEDIN 47 PEPTIDE AS A THERAPEUTIC AGENT | 2009 | Relief Therapeutics Holding SA | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Hiroshi Kawauchi | Kitasato University | 7 |
| 2 | Akiyoshi Takahashi | Kitasato University | 7 |
| 3 | Ludger Witte | Technische Universität Braunschweig | 4 |
| 4 | Tatjana Haitina | Uppsala University | 4 |
| 5 | Stephen O’Rahilly | University of Cambridge | 4 |
| 6 | Liga Zvejniece | University of Latvia | 4 |
| 7 | Ruta Muceniece | University of Latvia | 4 |
| 8 | Robert M. Dores | University of Denver | 4 |
| 9 | Maija Dambrova | Latvijas Organiskās Sintēzes Institūts | 4 |
| 10 | Victor J. Hruby | University of Arizona | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism | 2002 | 292 | Regulation of Appetite and Obesity |
| A POMC variant implicates β-melanocyte-stimulating hormone in the control of human energy balance | 2006 | 236 | Regulation of Appetite and Obesity |
| Prevalence, Spectrum, and Functional Characterization of Melanocortin-4 Receptor Gene Mutations in a Representative Population-Based Sample and Obese Adults from Germany | 2006 | 210 | Regulation of Appetite and Obesity |
| A role for β-melanocyte-stimulating hormone in human body-weight regulation | 2006 | 186 | Regulation of Appetite and Obesity |
| An Alu Element–Associated Hypermethylation Variant of the POMC Gene Is Associated with Childhood Obesity | 2012 | 178 | Epigenetics and DNA Methylation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Intermedine?
Which organizations hold the most patents related to Intermedine?
What therapeutic applications have been patented for Intermedine peptides?
What research topics are most represented in scientific publications about Intermedine?
How has patent activity for Intermedine changed in recent years?